RNAC logo

RNAC
Selecta Biosciences Inc

7,708
Mkt Cap
$171.51M
Volume
136,452.00
52W High
$15.57
52W Low
$5.60
PE Ratio
-1.29
RNAC Fundamentals
Price
$6.22
Prev Close
$6.47
Open
$6.41
50D MA
$6.88
Beta
1.83
Avg. Volume
284,681.56
EPS (Annual)
-$5.02
P/B
-1.33
Rev/Employee
$37,293.33
$74.80
Loading...
Loading...
News
all
press releases
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13h ago
News Placeholder
More News
News Placeholder
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday
Cartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-selecta-biosciences-inc-stock-1...
MarketBeat·15h ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One equities...
MarketBeat·10d ago
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·11d ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% Higher - Time to Buy?
Cartesian Therapeutics (NASDAQ:RNAC) Shares Up 10.3% - What's Next...
MarketBeat·13d ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·1mo ago
News Placeholder
Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush
Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price target on shares of Cartesian Therapeutics in a report on Monday...
MarketBeat·2mo ago
News Placeholder
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight
Cantor Fitzgerald raised Cartesian Therapeutics from a "neutral" rating to an "overweight" rating and set a $16.00 price target for the company in a research note on Monday...
MarketBeat·2mo ago
News Placeholder
Insights into Cartesian Therapeutics Q4 Earnings
read more...
Benzinga·2mo ago
<
1
2
...
>

Latest RNAC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.